ArriVent BioPharma Reports Full Year 2025 Financial Results
MWN-AI** Summary
ArriVent BioPharma, Inc. (Nasdaq: AVBP) recently announced its financial results for the year ended December 31, 2025, revealing significant progress in its clinical pipeline. The company reported cash and investments totaling $312.8 million, projected to sustain operations until Q3 2027, despite a net loss of $166.3 million for the year, up from $80.5 million in 2024. Research and development expenses surged to $153.4 million due to expanded clinical trials.
CEO Bing Yao highlighted promising advancements, particularly with firmonertinib, an oral EGFR inhibitor targeting rare mutations in non-small cell lung cancer (NSCLC). The company is currently conducting pivotal Phase 3 studies: the FURVENT trial, focusing on EGFR exon 20 insertion mutations, and the ALPACCA trial for PACC mutant NSCLC, with topline data expected by mid-2026. Yao emphasized firmonertinib's potential to be a standard of care without chemotherapy, supported by compelling CNS activity data.
ArriVent's pipeline also includes its first antibody-drug conjugate, ARR-217, now in Phase 1 trials for gastrointestinal cancers. The company received FDA IND clearance for ARR-217, indicating regulatory progress and an opportunity to expand its therapeutic offerings beyond lung cancer.
Additionally, firmonertinib gained NMPA approval in China for second-line treatment of NSCLC patients with EGFR exon 20 insertion mutations, further enhancing its market potential. As ArriVent focuses on delivering key clinical data and advancing its ADC programs, the company’s robust financial position underscores its capacity to drive innovation in cancer therapies amid ongoing challenges in treatment options for rare EGFR mutations.
MWN-AI** Analysis
ArriVent BioPharma (Nasdaq: AVBP) is navigating an interesting juncture in its trajectory as it pursues innovative therapeutics in oncology. The company's recent financial report for the year ending December 31, 2025, highlights significant advancements, particularly with firmonertinib, an oral EGFR inhibitor targeting difficult-to-treat non-small cell lung cancer (NSCLC) mutations. As the firm prepares for pivotal Phase 3 data announcements in mid-2026, investors should consider several factors before making investment decisions.
The financial outlook appears strong, with $312.8 million in cash and investments, enough to sustain operations through the third quarter of 2027. However, the increased net loss of $166.3 million in 2025—up from $80.5 million in 2024—raises operational sustainability concerns, necessitating close monitoring of R&D expenditures which surged significantly. While strong financial backing is a plus, the operational burn must align with advancing clinical milestones.
The upcoming topline data for firmonertinib's efficacy against EGFR exon 20 insertion mutations will be crucial. If positive, this could catalyze substantial stock movement, reflecting market enthusiasm for a potentially first-in-class treatment in an underserved patient population. Similarly, ongoing developments with ArriVent's antibody-drug conjugate portfolio, particularly ARR-217, could diversify its therapeutic offerings and mitigate perceived risks associated with dependence on firmonertinib alone.
Investors might want to adopt a cautious yet optimistic stance, acknowledging both the promising pipeline and potential volatility around clinical data releases. The overall market sentiment towards biotech firms continues to be influenced by regulatory outcomes and clinical efficacy, and judging by the current trajectory, ArriVent has positioned itself as a player to watch. Stay attuned to upcoming clinical milestones and financial health indicators when evaluating this stock.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026
- Global pivotal Phase 3 first-line PACC mutant NSCLC study for firmonertinib enrollment underway
- ADC pipeline advancing with first ADC program, ARR-217, in Phase 1 clinical development
- Cash and investments of $312.8 million as of December 31, 2025 expected to fund operations into 3Q 2027
NEWTOWN SQUARE, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the year ended December 31, 2025, and highlighted recent Company progress.
“We are advancing firmonertinib toward potential registration, supported by two pivotal programs targeting uncommon EGFR mutations in non-small cell lung cancer (NSCLC), a high unmet need with limited treatment options,” said Bing Yao, CEO of ArriVent. “Our robust clinical data, including CNS activity, underscores the potential of firmonertinib to become a chemotherapy-free standard of care. We look forward to topline pivotal data for firmonertinib monotherapy in frontline EGFR exon 20 insertion mutant NSCLC expected in mid-2026. This is an event driven study, so we plan to continue sharpening our timeline as we look forward to sharing our data.”
Dr. Yao continued, “Our antibody-drug conjugate (ADC) portfolio is also gaining momentum, led by ARR-217, a CDH17-targeted ADC currently in an ongoing Phase 1 trial, with best-in-class potential in gastrointestinal cancers. We expect additional ADC candidates to advance toward the clinic, broadening our pipeline beyond lung cancer into multiple additional solid tumor indications. Backed by a strong balance sheet and a projected cash runway into 3Q 2027, we are well positioned to deliver on our near-term catalysts.”
Recent and Full Year 2025 Highlights
Firmonertinib
- Dosed first in patient pivotal ALPACCA study. In December 2025, ArriVent announced dosing of the first patient in the global pivotal Phase 3 ALPACCA study evaluating firmonertinib monotherapy for first-line treatment of epidermal growth factor receptor (EGFR) PACC mutant non-small cell lung cancer (NSCLC) (NCT07185997).
- Positive final data in EGFR PACC mutant NSCLC. In September 2025, ArriVent presented positive final proof-of-concept data from the randomized global Phase 1b FURTHER trial cohort of first-line firmonertinib monotherapy in patients with NSCLC harboring EGFR PACC mutations at the 2025 World Conference on Lung Cancer (WCLC) (NCT05364073). Firmonertinib demonstrated clinically meaningful progression free survival, central nervous system (CNS) complete responses, and a manageable safety profile consistent with previous trials. We believe this to be the first clinical dataset testing an EGFR inhibitor in a prospectively defined population of EGFR PACC mutant NSCLC.
- Completed enrollment for pivotal FURVENT trial. During the first quarter of 2025, we completed enrollment in the global pivotal Phase 3 FURVENT study of firmonertinib monotherapy in first-line NSCLC EGFR exon 20 insertion mutations (NCT05607550). Firmonertinib, an oral, highly brain-penetrant, and broadly active mutation-selective EGFR inhibitor, received Food and Drug Administration (FDA) Breakthrough Therapy Designation in this patient population.
- Received National Medical Products Administration (NMPA) approval in China in second-line EGFR exon 20 insertion mutations. In February 2026, our partner Shanghai Allist Pharmaceutical Technology Co., Ltd., received NMPA approval for firmonertinib for adults with locally advanced or metastatic NSCLC who have progressed on or after prior platinum-based chemotherapy or who are intolerant to platinum-based chemotherapy and who have been tested for the presence of EGFR exon 20 insertion mutations.
Pipeline
- Clinical advancement of ADC lead ARR-217 (MRG007). Ongoing Phase 1 dose escalation for ARR-217, a CDH17 targeted ADC, in gastrointestinal malignancies in partnership with Lepu Biopharma Co., Ltd. ArriVent also received FDA IND clearance for ARR-217 and dosed its first patient in March 2026.
Upcoming Milestones
- Firmonertinib pivotal EGFR exon 20 insertions data. Top-line firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study for first-line EGFR exon 20 insertions mutant NSCLC is projected to be in mid-2026.
- IND filing for ARR-002. U.S. IND filing for first-in-class ADC program planned for first half 2026. Plan to present preclinical data at an upcoming conference.
- Complete Phase 1 dose escalation for ARR-217. Plan to complete Phase 1 dose escalation and enter into dose optimization for ARR-217, a CDH17 targeting ADC program, in the second half of 2026.
2025 Financial Results
- As of December 31, 2025, the Company had cash and investments of $312.8 million, which is expected to fund operations into 3Q 2027.
- Net cash used in operations was $160.6 million and $70.2 million for the years ended December 31, 2025 and 2024, respectively.
- Research and development expenses were $153.4 million and $79.0 million for the years ended December 31, 2025 and 2024, respectively. The research and development expenses in 2025 include a one-time upfront payment to Lepu Biopharma Co., Ltd.
- General and administrative expenses were $24.2 million and $15.3 million for the years ended December 31, 2025 and 2024, respectively.
- Net loss was $166.3 million and $80.5 million for the years ended December 31, 2025 and 2024, respectively.
About ArriVent
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.
About Firmonertinib
Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. In March 2021, firmonertinib was approved in China for first-line advanced non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletion or L858R mutations and for patients with previously treated locally advanced or metastatic NSCLC with EGFR T790M mutation, otherwise known as EGFR classical mutations.
Firmonertinib was granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for the treatment of patients with previously untreated locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations. Firmonertinib was also granted U.S. FDA Orphan Drug Designation for the treatment of NSCLC with EGFR mutations or human epidermal growth factor receptor 2 (HER2) mutations or HER4 mutations.
Firmonertinib is currently being studied in a global Phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and in a global Phase 3 study in first line NSCLC patients with EGFR PACC mutations (ALPACCA; NCT07185997).
About EGFR mutant NSCLC
Globally, lung cancer is the leading cause of cancer-related deaths among men and women. NSCLC is the predominant subtype of lung cancer, accounting for approximately 85% of all cases. Mutational activation of the EGFR is a frequent and early event in the development of NSCLC. EGFR mutations are divided into classical and uncommon. EGFR exon 20 insertion mutations are a group of uncommon EGFR mutations and constitute approximately 9% of all EGFR mutations. PACC mutations are another group of uncommon EGFR mutations and represent approximately 12% of all EGFR mutations. Patients with NSCLC whose tumors harbor uncommon EGFR mutations have significantly lower life expectancy with available therapies and represent an area of unmet medical need.
About EGFR PACC mutations
P-loop and ?C-helix compressing (PACC) EGFR mutations are a distinct set of approximately 70 mostly missense activating mutations within the kinase domain of EGFR. They are similar to exon 20 insertion mutations in narrowing the drug binding pocket to affect tyrosine kinase inhibitor activity. PACC mutations are diagnosed through commercially available NGS and most PCR tests. Patients with PACC mutations have limited treatment options, and there is no broadly utilized standard of care treatment for first-line PACC mutant patients.
About FURVENT
FURVENT is a global, pivotal 3 arm Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with exon 20 insertion mutations being conducted jointly with our partner Allist (NCT05607550). The FURVENT clinical trial is designed to assess the safety and efficacy of firmonertinib administered at either 160 mg or 240 mg, once-daily with each dose being compared to platinum-based chemotherapy with pemetrexed, the current first-line standard of care. The primary endpoint of this study is PFS by BICR per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Secondary endpoints in patients with brain metastases at baseline include brain-specific CNS overall response rate (CNS-ORR) and CNS-PFS by modified RECIST (mRECIST). The study enrolled 398 patients globally, including from sites in the United States, Europe and certain Asian countries including Japan and China.
About ALPACCA
ALPACCA is a global, pivotal 2 arm Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with PACC mutations being conducted jointly with our partner Allist (NCT07185997). The ALPACCA trial is evaluating firmonertinib 240 mg once daily versus investigator’s choice of osimertinib or afatinib in first-line patients with EGFR PACC mutant NSCLC. The 240 mg dose of firmonertinib was selected for pivotal development based on compelling data showing a 16-month median PFS and a confirmed 68% ORR by BICR in the FURTHER trial (NCT05364073). The primary endpoints of this study are ORR and PFS by BICR per RECIST.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, cash runway, estimates of our addressable market, activity of firmonertinib compared to available therapies, anticipated clinical milestones, the timing of, and results of, top-line pivotal Phase 3 data for firmonertinib in previously untreated NSCLC patients whose tumors contain EGFR exon 20 insertion mutations, the timing of our planned enrollment of the global pivotal Phase 3 study of firmonertinib in previously untreated NSCLC patients whose tumors contain EGFR PACC mutations, the advancement of the Phase 1 study for ARR-217 in gastrointestinal tumors and the timing of presentation of data from that study, the timing of U.S. IND filing for ARR-002, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2025, to be filed with the Securities and Exchange Commission on March 5, 2026 and our other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law.
| ARRIVENT BIOPHARMA, INC. | ||||||||
| BALANCE SHEETS | ||||||||
| (in thousands, except share and per share data) | ||||||||
| (Unaudited) | ||||||||
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 45,540 | $ | 74,293 | ||||
| Short-term investments | 267,281 | 144,570 | ||||||
| Prepaid expenses and other current assets | 20,076 | 8,116 | ||||||
| Total current assets | 332,897 | 226,979 | ||||||
| Long-term investments | — | 47,683 | ||||||
| Right of use assets – operating leases | 13 | 154 | ||||||
| Deferred offering costs | 69 | — | ||||||
| Other assets | 190 | 126 | ||||||
| Total assets | $ | 333,169 | $ | 274,942 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 5,934 | $ | 3,782 | ||||
| Accrued expenses | 19,997 | 13,330 | ||||||
| Operating lease liabilities | 14 | 162 | ||||||
| Total current liabilities | 25,945 | 17,274 | ||||||
| Operating lease liabilities, net of current amount | — | 14 | ||||||
| Total liabilities | 25,945 | 17,288 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding | — | — | ||||||
| Common stock $0.0001 par value, 200,000,000 shares authorized; 42,452,251 and 33,706,765 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 4 | 3 | ||||||
| Additional paid-in capital | 711,847 | 496,195 | ||||||
| Accumulated deficit | (404,641 | ) | (238,333 | ) | ||||
| Accumulated other comprehensive income (loss) | 14 | (211 | ) | |||||
| Total stockholders’ equity | 307,224 | 257,654 | ||||||
| Total liabilities and stockholders’ equity | $ | 333,169 | $ | 274,942 |
| ARRIVENT BIOPHARMA, INC. | ||||||||
| STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||
| (in thousands, except share and per share data) | ||||||||
| (Unaudited) | ||||||||
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 153,351 | $ | 79,004 | ||||
| General and administrative | 24,183 | 15,304 | ||||||
| Total operating expenses | 177,534 | 94,308 | ||||||
| Operating loss | (177,534 | ) | (94,308 | ) | ||||
| Interest and investment income | 11,226 | 13,820 | ||||||
| Net loss | (166,308 | ) | (80,488 | ) | ||||
| Unrealized gain (loss) on marketable securities | 225 | (211 | ) | |||||
| Total other comprehensive gain (loss) | 225 | (211 | ) | |||||
| Total comprehensive loss | $ | (166,083 | ) | $ | (80,699 | ) | ||
| Share information: | ||||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (4.32 | ) | $ | (2.56 | ) | ||
| Weighted-average shares of common stock outstanding, basic and diluted | 38,462,600 | 31,469,328 |
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
FAQ**
What potential implications could the topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC, expected mid-2026, have for ArriVent BioPharma Inc. (AVBP) stock value and market position?
How might the positive proof-of-concept data presented for firmonertinib in EGFR PACC mutant NSCLC impact investor sentiment towards ArriVent BioPharma Inc. (AVBP) as they approach pivotal trial data releases?
Given ArriVent BioPharma Inc. (AVBP) has a projected cash runway into 2027, how will this financial outlook affect their ability to fund ongoing and future clinical trials, particularly for firmonertinib and their ADC pipeline?
What strategies is ArriVent BioPharma Inc. (AVBP) implementing to mitigate risks associated with the outcome of the FURVENT and ALPACCA trials, and how could these strategies affect investor confidence leading up to the data releases?
**MWN-AI FAQ is based on asking OpenAI questions about ArriVent BioPharma Inc. (NASDAQ: AVBP).
NASDAQ: AVBP
AVBP Trading
-5.73% G/L:
$25.075 Last:
292,138 Volume:
$25.33 Open:
